REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants

REGENXBIO Inc. (Nasdaq: RGNX) has announced the pricing of an underwritten public offering aimed at raising approximately $100 million. The offering includes 10,003,889 shares of common stock priced at $9.00 per share, along with 1,111,111 pre-funded warrants priced at $8.9999 each. The gross proceeds from this transaction are expected to be around $100 million, with the offering anticipated to close on July 20, 2026, subject to customary closing conditions. The underwriters have also been granted a 30-day option to purchase an additional 1,667,250 shares at the public offering price.

REGENXBIO is a biotechnology company focused on advancing gene therapy solutions, particularly through its proprietary adeno-associated virus (AAV) platform. Founded in 2009, the company has established a robust pipeline of gene therapies targeting rare diseases and retinal conditions. Notable products in development include RGX-202 for Duchenne muscular dystrophy and ABBV-RGX-314, a collaboration with AbbVie for the treatment of wet age-related macular degeneration (AMD) and diabetic retinopathy. The company’s innovative approach has positioned it as a leader in the gene therapy sector, with thousands of patients having received treatments derived from its AAV platform.

The strategic rationale behind this public offering is likely to bolster REGENXBIO's financial position to support its ongoing clinical trials and accelerate the development of its gene therapy pipeline. As the biotechnology sector continues to evolve, companies like REGENXBIO are increasingly reliant on capital markets to fund research and development initiatives. The successful execution of this offering could enhance REGENXBIO's ability to bring its innovative therapies to market, especially as it navigates the complexities of regulatory approvals and competition in the gene therapy landscape.

The broader market implications of this offering reflect a growing trend among biotech firms to leverage public offerings as a means of financing. With an increasing number of companies in the sector pursuing IPOs and public offerings, investor interest in gene therapy and biotechnology remains robust. This transaction underscores the confidence in the potential of gene therapies to transform treatment paradigms, particularly for rare diseases, which often lack effective treatment options. As the market continues to mature, REGENXBIO’s successful capital raise may serve as a benchmark for other biotech firms looking to access public markets for growth and innovation.